Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PN2034 in Type 2 Diabetes on Rosiglitazone and Metformin
NCT00110851Phase 2Completed
- Sponsor
- Wellstat Therapeutics Corporation
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing PN2034 Arm with Placebo Arm (2 arms). Primary endpoints: Glycosylated Hemoglobin at 12 weeks and Safety. Started Apr 2005; status: completed.
02
Drugs
PN-2034
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00110851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110851.